Phase 1/2 clinical study of irinotecan and oral S-1 (IRIS) in patients with advanced gastric cancer

Advances in Therapy

Volumn 27, Issue 7, 2010, Pages 483-492

  Komatsu, Yoshito ^a   Yuki, Satoshi ^a   Fuse, Nozomu ^a   Kato, Takashi ^a   Miyagishima, Takuto ^a   Kudo, Mineo ^a   Kunieda, Yasuyuki ^a   Tateyama, Miki ^a   Wakahama, Osamu ^a   Meguro, Takashi ^a   Sakata, Yuh ^b   Asaka, Masahiro ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Misawa City Hospital   (Japan)

Author keywords

clinical trial; gastric cancer; irinotecan; phase 1 2; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; HANGESHASHIN TO; HERBACEOUS AGENT; IRINOTECAN; TOPOCETIN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BEDTIME DOSAGE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DERMATITIS; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; MORNING DOSAGE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; STOMACH CANCER; SURVIVAL TIME; THROMBOCYTE COUNT;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OXONIC ACID; STOMACH NEOPLASMS; TEGAFUR; YOUNG ADULT;

EID: 77956228289     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-010-0037-2     Document Type: Article

References (35)

1. A.M. Murad F.F. Santiago A. Petroianu P.R. Rocha M.A. Rodrigues M. Rausch 1993 Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer Cancer 72 37 41 10.1002/1097-0142(19930701)72:1<37:: AID-CNCR2820720109>3.0.CO;2-P 1:STN:280:DyaK3s3osVGqtQ%3D%3D 8508427
2. B. Glimelius K. Hoffman U. Haglund O. Nyrén P.O. Sjödén 1994 Initial or delayed chemotherapy with best supportive care in advanced gastric cancer Ann Oncol 5 189 90 1:STN:280: DyaK2c3kt1KrsA%3D%3D 8186165
3. S. Pyrhönen T. Kuitunen P. Nyandoto M. Kouri 1995 Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer Br J Cancer 71 587 591 7533517
4. P. Chollet P. Schöffski K. Weigang-Köhler 2003 Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECDG) Eur J Cancer 39 1264 1270 10.1016/S0959-8049(03)00237-5 1:CAS:528:DC%2BD3sXjvFelurs%3D 12763215
5. Y. Sakata A. Ohtsu N. Horikoshi K. Sugimachi Y. Mitachi T. Taguchi 1998 Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients Eur J Cancer 34 1715 1720 10.1016/S0959-8049(98)00211-1 1:CAS:528:DyaK1cXntlShurw%3D 9893658
6. N. Boku S. Yamamoto H. Fukuda 2009 Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study Lancet Oncol 10 1027 1028 10.1016/S1470-2045(09)70259-1
7. W. Koizumi H. Narahara T. Hara 2008 S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial Lancet Oncol 9 215 221 10.1016/S1470-2045(08)70035-4 1:CAS:528: DC%2BD1cXivVaqtb4%3D 18282805
8. Y. Shimada M. Yoshino A. Wakui 1993 Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer J Clin Oncol 11 909 913 1:STN:280:DyaK3s3ltlCgtw%3D%3D 8487053
9. M.L. Rothenberg J.R. Eckardt J.G. Kuhn 1996 Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer J Clin Oncol 14 1128 1135 1:CAS:528:DyaK28XisFyksbY%3D 8648367
10. K. Futatsuki A. Wakui I. Nakao 1994 Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group Gan To Kagaku Ryoho 21 1033 1038 1:STN:280: DyaK2c3ntVyisg%3D%3D 8210254
11. C.H. Köhne R. Catane B. Klein 2003 Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial Br J Cancer 89 997 1001 10.1038/sj.bjc.6601226 12966415
12. N. Boku A. Ohtsu Y. Shimada 1999 Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer J Clin Oncol 17 319 323 1:CAS:528:DyaK1MXltVyrtg%3D%3D 10458249
13. C.D. Blanke D.G. Haller A.B. Benson 2001 A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma Ann Oncol 12 1575 1580 10.1023/A:1013129315036 1:STN:280:DC%2BD38%2FptlGiug%3D%3D 11822757
14. H. Joel M. Parson R. Lee 1999 A phase II trial of irinotecan (CPT-11) in patients with adenocarcinoma of the esophagus and gastric cardia Proc Am Soc Clin Oncol 18 1100
15. M.P.N. Findlay S. Ackland V. Gebski 2001 Phase II study of irinotecan, leucovorin and 5FU (ILF) in advanced gastric cancer Proc Am Soc Clin Oncol 20 655
16. L.B. Saltz J.V. Cox C. Blanke 2000 Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group N Engl J Med 343 905 914 10.1056/NEJM200009283431302 1:CAS:528:DC%2BD3cXntFOkt7Y%3D 11006366
17. J.Y. Douillard D. Cunningham A.D. Roth 2000 Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial Lancet 355 1041 1047 10.1016/S0140-6736(00)02034-1 1:CAS:528:DC%2BD3cXisFOnsb4%3D 10744089
18. A. Ohtsu N. Boku T. Yoshioka 2003 A phase II study of irinotecan in combination with 120-h infusion of 5-fluorouracil in patients with metastatic colorectal carcinoma: Japan Clinical Oncology Group Study (JCOG9703) Jpn J Clin Oncol 33 28 32 10.1093/jjco/hyg003 12604721
19. Y. Komatsu H. Takeda M. Takei 2002 A phase 1 and PK study of S-1 and irinotecan (CPT-11) in patients with advanced gastric cancer (AGC) Proc Am Soc Clin Oncol 21 Abstract 683
20. Y. Yamada H. Yasui A. Goto 2003 Phase I study of irinotecan and S-1 combination therapy in patients with metastatic gastric cancer Int J Clin Oncol 8 374 80 10.1007/s10147-003-0359-z 1:CAS:528:DC%2BD3sXps1SgsLg%3D 14663640
21. H. Takiuchi H. Narahara T. Tsujinaka 2005 Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced gastric cancer (OGSG 0002) Jpn J Clin Oncol 35 520 525 10.1093/jjco/hyi148 16141295
22. M. Inokuchi T. Yamashita H. Yamada 2006 Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer Br J Cancer 94 1130 1135 10.1038/sj.bjc.6603072 1:CAS:528:DC%2BD28XjsFaksLo%3D 16570038
23. N. Uedo H. Narahara R. Ishihara 2007 Phase II study of a combination of irinotecan and S-1 in patients with advanced gastric cancer (OGSG0002) Oncology 73 65 71 10.1159/000120630 1:CAS:528:DC%2BD1cXktVSgt74%3D 18334851
24. M. Ikeda H. Furukawa H. Imamura 2002 Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function Cancer Chemother Pharmacol 50 25 32 10.1007/s00280-002- 0457-z 1:CAS:528:DC%2BD38XkvVagu70%3D 12111108
25. National Cancer Institute Common Toxicity Criteria (NCI-CTC). Version 2.0. April 30, 1999. Available at: http://ctep.cancer.gov/protocoldevelopment/ electronic-applications/docs/ctcv20-4-30-992.pdf. Last accessed 17 May 2010.
26. P. Therasse S.G. Arbuck E.A. Eisenhauer 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10655437
27. W. Koizumi M. Kurihara S. Nakano K. Hasegawa 2000 Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group Oncology 58 191 197 10.1159/000012099 1:CAS:528:DC%2BD3cXjvVeitr4%3D 10765119
28. A. Beck M.C. Etienne S. Chéradame 1994 A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil Eur J Cancer 30A 1517 1522 10.1016/0959-8049(94)00216-R 1:CAS:528:DyaK2MXit1Wls7o%3D 7833111
29. P.G. Johnston H.J. Lenz C.G. Leichman 1995 Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors Cancer Res 55 1407 1412 1:CAS:528:DyaK2MXkslWis7c%3D 7882343
30. W. Ichikawa T. Takahashi K. Suto 2004 Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer Br J Cancer 91 1245 1250 10.1038/sj.bjc.6602139 1:CAS:528:DC%2BD2cXnvFCgtbs%3D 15354215
31. Imamura H, Iiishi H, Tsuburaya A, et al. Randomized phase III study of irinotecan plus S-1 (IRIS) versus S-1 alone as first-line treatment for advanced gastric cancer (GC0301/TOP-002). Abstract 5. Presented at: 2008 ASCO Gastrointestinal Cancers Symposium. Available at: http://www.asco.org/ASCOv2/ Meetings/Abstracts?&vmview=abst-detail-view&confID=53&abstractID= 10303.
32. Y. Komatsu S. Yuki I. Iwanaga 2008 Phase II clinical study of combination therapy with irinotecan and S-1 (IRIS) for inoperable recurrent advanced colorectal cancer: Hokkaido Gastrointestinal Cancer Study Group study HGCSG-0302, final analysis Ann Oncol 19suppl.8 viii125 viii152
33. K. Shitara Y. Komatsu S. Yuki 2008 Pilot study of combination chemotherapy using irinotecan plus S-1 for metastatic pancreatic cancer Oncology 75 67 70 10.1159/000151742 1:CAS:528:DC%2BD1cXhtFKgsrbO 18753799
34. K. Mori T. Kondo Y. Kamiyama Y. Kano K. Tominaga 2003 Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer Cancer Chemother Pharmacol 51 403 406 1:CAS:528:DC%2BD3sXjsVOqsrw%3D 12687289
35. K. Takasuna T. Hagiwara K. Watanabe 2006 Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea Cancer Chemother Pharmacol 58 494 503 10.1007/s00280-006-0187-8 1:CAS:528:DC%2BD28XmsVShtL0%3D 16437251